{"protocolSection":{"identificationModule":{"nctId":"NCT00370292","orgStudyIdInfo":{"id":"10940"},"secondaryIdInfos":[{"id":"H3E-IT-S105"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial"},"statusModule":{"statusVerifiedDate":"2009-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-09"},"primaryCompletionDateStruct":{"date":"2008-09","type":"ACTUAL"},"completionDateStruct":{"date":"2008-09","type":"ACTUAL"},"studyFirstSubmitDate":"2006-08-29","studyFirstSubmitQcDate":"2006-08-29","studyFirstPostDateStruct":{"date":"2006-08-31","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-09-09","resultsFirstSubmitQcDate":"2009-09-09","resultsFirstPostDateStruct":{"date":"2009-10-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-10-15","lastUpdatePostDateStruct":{"date":"2009-10-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":19,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed - Before Protocol Amendment","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed - Before Protocol Amendment"]},{"label":"Pemetrexed - After Protocol Amendment","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed - After Protocol Amendment"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed - Before Protocol Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue","armGroupLabels":["Pemetrexed - Before Protocol Amendment"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"Pemetrexed - After Protocol Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.","armGroupLabels":["Pemetrexed - After Protocol Amendment"],"otherNames":["LY231514","Alimta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3","description":"dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \\[PCR\\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).","timeFrame":"pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)"},{"measure":"Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3","description":"dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \\[PCR\\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).","timeFrame":"pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)"}],"secondaryOutcomes":[{"measure":"Best Objective Tumor Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","timeFrame":"baseline to measured response (every 14 days for 6 cycles)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Histologically or cytologically proven IIIB and IV NSCLC.\n* No symptomatic uncontrolled brain metastasis\n* Not suitable for platinum containing regimens if chemo-naive\n* Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale.\n* Creatinine Clearance (CrCl) greater than or equal to 45 milliliters per min (mL/min)\n\nExclusion Criteria\n\n* Prior radiation to greater than 25% of bone marrow\n* Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period.\n* Presence of clinically relevant third-space fluid collections not controllable.\n* Significant cardiac disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of the 19 enrolled patients, 12 were enrolled before the protocol amendment was made effective (i.e. 2-weekly administration) and 7 were enrolled after the amendment (i.e. 3-weekly administration).","groups":[{"id":"FG000","title":"Pemetrexed","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles (pre-amendement) or 21 days x 6 cycles (post-amendment) or disease progression, unacceptable toxicity or patient decision to discontinue."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"19"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed - Before Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue."},{"id":"BG001","title":"Pemetrexed - After Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.1","spread":"10.34"},{"groupId":"BG001","value":"69.4","spread":"6.45"},{"groupId":"BG002","value":"69.2","spread":"8.90"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Disease Stages","description":"Stage means how big the tumor is and how far it's spread. Stages range from 0 (tumor has not spread) to IV (tumor has spread to other organs).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Not Known","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage IA","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"Stage IB","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage IIA","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage IIB","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}]}]},{"title":"Eastern Cooperative Oncology Group Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]},{"title":"2 - Ambulatory, No Work Activities","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Histopathological Grade","description":"Assesses the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. Grades range from 1 (least aggressive and best prognosis) to 4 (most aggressive and worst prognosis).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Not Done","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"}]}]},{"title":"G1 - Well-Differentiated","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"G2 - Moderately Differentiated","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]},{"title":"G3 - Poorly Differentiated","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Previous Anti-Tumor Treatment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]}]},{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}]}]}]},{"title":"Previous Surgery","description":"Participants having surgery could have more than one type of surgery.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Surgery - No","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}]},{"title":"Surgery - Yes: Pneumonectomy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Surgery - Yes: Lobectomy","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"Surgery - Yes: Other","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}]},{"title":"Surgery - Yes: Radical","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}]}]},{"title":"Race/Ethnicity","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Tumor Type","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}]},{"title":"Squamous Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Blood Pressure","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mmHg","classes":[{"title":"Systolic Blood Pressure (SBP)","categories":[{"measurements":[{"groupId":"BG000","value":"138.0","spread":"13.17"},{"groupId":"BG001","value":"146.9","spread":"21.54"},{"groupId":"BG002","value":"141.6","spread":"17.08"}]}]},{"title":"Diastolic Blood Pressure (DBP)","categories":[{"measurements":[{"groupId":"BG000","value":"81.8","spread":"7.97"},{"groupId":"BG001","value":"83.6","spread":"9.45"},{"groupId":"BG002","value":"82.5","spread":"8.37"}]}]}]},{"title":"Body Surface Area (BSA)","description":"BSA = 0.007184 x weight(kg)\\^0.425 x height(cm)\\^0.725","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"square meters (m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.7","spread":"0.17"},{"groupId":"BG001","value":"1.7","spread":"0.13"},{"groupId":"BG002","value":"1.7","spread":"0.16"}]}]}]},{"title":"Body Temperature","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"degrees Celsius (Â°C)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.1","spread":"0.58"},{"groupId":"BG001","value":"35.9","spread":"0.36"},{"groupId":"BG002","value":"36.0","spread":"0.49"}]}]}]},{"title":"Heart Rate","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"beats per minute (bpm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"82.9","spread":"14.98"},{"groupId":"BG001","value":"78.6","spread":"8.52"},{"groupId":"BG002","value":"81.1","spread":"12.58"}]}]}]},{"title":"Height","description":"One participant in the Pemetrexed - Before Amendment group was missing a baseline height measurement.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"169.2","spread":"10.15"},{"groupId":"BG001","value":"162.1","spread":"9.04"},{"groupId":"BG002","value":"166.4","spread":"10.09"}]}]}]},{"title":"Weight","description":"One participant in the Pemetrexed - Before Amendment group was missing a baseline weight measurement.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.2","spread":"15.28"},{"groupId":"BG001","value":"66.3","spread":"9.43"},{"groupId":"BG002","value":"68.7","spread":"13.13"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3","description":"dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \\[PCR\\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).","populationDescription":"All participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mRNA relative values (ratio with GAPDH)","timeFrame":"pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)","groups":[{"id":"OG000","title":"dCK - Cycle 1","description":"Mean dCK expression evaluated at Cycle 1."},{"id":"OG001","title":"dCK - Cycle 2","description":"Mean dCK expression evaluated at Cycle 2."},{"id":"OG002","title":"dCK - Cycle 3","description":"Mean dCK expression evaluated at Cycle 3."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"19"}]}],"classes":[{"title":"Pre-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"0.03"},{"groupId":"OG001","value":"0.92","spread":"0.03"},{"groupId":"OG002","value":"0.92","spread":"0.02"}]}]},{"title":"1 Hour Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.04"},{"groupId":"OG001","value":"0.95","spread":"0.03"},{"groupId":"OG002","value":"0.96","spread":"0.03"}]}]},{"title":"2 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.04"},{"groupId":"OG001","value":"0.96","spread":"0.04"},{"groupId":"OG002","value":"0.97","spread":"0.02"}]}]},{"title":"4 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"0.04"},{"groupId":"OG001","value":"0.94","spread":"0.04"},{"groupId":"OG002","value":"0.92","spread":"0.03"}]}]},{"title":"6 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"0.03"},{"groupId":"OG001","value":"0.91","spread":"0.04"},{"groupId":"OG002","value":"0.91","spread":"0.03"}]}]},{"title":"24 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.04"},{"groupId":"OG001","value":"0.97","spread":"0.03"},{"groupId":"OG002","value":"0.96","spread":"0.03"}]}]},{"title":"48 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.04"},{"groupId":"OG001","value":"0.96","spread":"0.04"},{"groupId":"OG002","value":"0.97","spread":"0.03"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 1 Hour Post-Dose (1 hour across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 2 Hours Post-Dose (2 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.030","pValueComment":"P-value for 4 Hours Post-Dose (4 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.166","pValueComment":"P-value for 6 Hours Post-Dose (6 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 24 Hours Post-Dose (24 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 48 Hours Post-Dose (48 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Best Objective Tumor Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","populationDescription":"Number of participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline to measured response (every 14 days for 6 cycles)","groups":[{"id":"OG000","title":"Pemetrexed - Before Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue."},{"id":"OG001","title":"Pemetrexed - After Amendment","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}],"classes":[{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Early Death","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Unconfirmed Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"PRIMARY","title":"Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3","description":"dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \\[PCR\\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).","populationDescription":"Number of participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mRNA relative values (ratio with GAPDH)","timeFrame":"pre-dose, 1, 2, 4, 6, 24, and 48 hours post-dose (3 cycles)","groups":[{"id":"OG000","title":"hENT - Cycle 1","description":"Mean hENT expression evaluated at Cycle 1."},{"id":"OG001","title":"hENT - Cycle 2","description":"Mean hENT expression evaluated at Cycle 2."},{"id":"OG002","title":"hENT - Cycle 3","description":"Mean hENT expression evaluated at Cycle 3."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"19"}]}],"classes":[{"title":"Pre-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.03"},{"groupId":"OG001","value":"0.86","spread":"0.03"},{"groupId":"OG002","value":"0.87","spread":"0.02"}]}]},{"title":"1 Hour Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.04"},{"groupId":"OG001","value":"0.89","spread":"0.04"},{"groupId":"OG002","value":"0.90","spread":"0.03"}]}]},{"title":"2 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.04"},{"groupId":"OG001","value":"0.90","spread":"0.04"},{"groupId":"OG002","value":"0.90","spread":"0.04"}]}]},{"title":"4 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.04"},{"groupId":"OG001","value":"0.88","spread":"0.05"},{"groupId":"OG002","value":"0.86","spread":"0.03"}]}]},{"title":"6 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.04"},{"groupId":"OG001","value":"0.86","spread":"0.04"},{"groupId":"OG002","value":"0.86","spread":"0.02"}]}]},{"title":"24 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.04"},{"groupId":"OG001","value":"0.91","spread":"0.04"},{"groupId":"OG002","value":"0.91","spread":"0.02"}]}]},{"title":"48 Hours Post-Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"0.04"},{"groupId":"OG001","value":"0.91","spread":"0.04"},{"groupId":"OG002","value":"0.91","spread":"0.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 1 Hour Post-Dose (1 hour across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 2 Hours Post-Dose (2 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.333","pValueComment":"P-value for 4 Hours Post-Dose (4 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.849","pValueComment":"P-value for 6 Hours Post-Dose (6 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 24 Hours Post-Dose (24 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"},{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 48 Hours Post-Dose (48 hours across cycles compared with pre-dose across cycles).","statisticalMethod":"Repeated Measures Analysis of Variance","ciPctValue":"95"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed","description":"500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles (pre-amendement) or 21 days x 6 cycles (post-amendment) or disease progression, unacceptable toxicity or patient decision to discontinue.","seriousNumAffected":5,"seriousNumAtRisk":19,"otherNumAffected":19,"otherNumAtRisk":19}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":19}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":19}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Petechiae","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":19}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":19}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":19}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":19}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":19}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":19}]},{"term":"Salivary gland calculus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":19}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":19}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":19}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":19}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":19}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":14,"numAtRisk":19}]},{"term":"Omphalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Transaminases","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":19}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":19}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":19}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Balanitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":19}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":19}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":19}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Epistaxis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}